We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » EMA Q&A Addresses Devices and Integrated Medicines

EMA Q&A Addresses Devices and Integrated Medicines

June 20, 2024

An EMA Q&A document provides advice on how to develop medical devices that incorporate a medicinal substance or an in vitro diagnostic.

For medical devices that form an integral product with a medicinal product, developers are now required to provide an EU declaration of conformity, a certificate of conformity, or an opinion from a notified body designated for the type of device in question are applicable in certain circumstances.

Read the Q&A here.

To read the whole story, click here.

Related Topics

Devices Regulatory Affairs

    Upcoming Events

    • 20Jun

      Inspection Readiness for EU GMP Annex 1 – Manufacture of Sterile Medicinal Products

    • 26Jun

      Streamlining Clinical Trial Agreement Negotiations: Avoiding Common Pitfalls for Faster Signatures

    • 27Jun

      Gene Editing at the Cutting Edge of Molecular Medicine: Clinical, Ethical, and Biosafety Concerns in CRISPR Clinical Trials

    • 11Jul

      Postmarket Surveillance in the Real World: The FDA’s Perspective on RWD/RWE

    • 18Jul

      AI/ML in Medical Devices: U.S. and EU Regulatory Perspectives

    • 21Oct

      MAGI@home Clinical Research Conference 2024

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • FDA Gets Feedback at Meeting on AdComm Makeup and Processes

    • Class I Recalls for Arrow Cardiac Balloon Catheters, Getinge Anesthesia Vaporizers

    • FDA Form 483 Dings Florida Compounder for Recurring Problems

    • EMA Q&A Addresses Devices and Integrated Medicines

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing